The global checkpoint inhibitors for anti-cancer treatment market is estimated to have reached $11.43 bn in 2018 and is expected to grow at a CAGR of 13.7% during the forecast period.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 152-page report you will receive 72 tables and 32 figures– all unavailable elsewhere.
The 152-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029
• Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Leading Drugs: • Yervoy (ipilimumab) • Opdivo (nivolumab) • Keytruda (pembrolizumab)
• Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Class: • CTLA-4 Inhibitors • PD-1 Inhibitors • Pipeline Drugs
• Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by regional and national market: • U.S. • EU: Germany, France, Italy, U.K., Spain • Japan • APAC
• Profiles of the selected leading companies: • AstraZeneca, Plc • Bristol-Myers Squibb Co. • Celldex Therapeutics, Inc. • Incyte Corporation • Merck & Co., Inc. • Novartis AG • Pfizer, Inc. • Roche Holding AG
• The Checkpoint Inhibitors Anti-Cancer Treatment Market Pipeline Analysis
• A SWOT analysis of the global checkpoint inhibitors anti-cancer treatment market
• Key Questions Answered by this Report: • What are the global revenue prospects for the period 2018 to 2029? • What are the leading national market potentials from 2018 to 2029? • How is the checkpoint inhibitor anti-cancer treatment drugs market evolving? • What is driving and restraining the checkpoint inhibitor anti-cancer treatment drugs market? • What are the market shares of each segment of the overall checkpoint inhibitor anti-cancer treatment drugs market? • How will main checkpoint inhibitor anti-cancer treatment submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029? • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029? • Which therapies can succeed and what revenues could they generate to 2029? • What will be the main commercial drivers for the market from 2018 to 2029? • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth? • How will that industry evolve between 2018 and 2029, especially in R&D?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2018
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to the Checkpoint Inhibitor Anti-Cancer Treatment Drugs World Market 2018
2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
2.2 Checkpoint Inhibitor Treatment Drugs in Oncology
2.3 Application Segment
2.3.1 Lung Cancer
2.3.2 Bladder Cancer
2.3.3 Melanoma
2.3.4 Hodgkin Lymphoma
3. Leading Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market Forecasts 2019-2029 and Leading Companies in the World Market
3.1 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs in the Market 2019
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes 3D Cell Culture and 3D Bioprinting Market Report 2023-2033
The global 3D Cell Culture and 3D Bioprinting market is valued at US$2,277.2 million in 2023 and is projected to grow at a CAGR of 17.8% during the forecast period 2023-2033.
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
